<?xml version='1.0' encoding='UTF-8'?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <!--The publisher of this article does not allow downloading of the full text in XML form.-->
  <?properties manuscript?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-journal-id">101761119</journal-id>
      <journal-id journal-id-type="pubmed-jr-id">49159</journal-id>
      <journal-id journal-id-type="nlm-ta">Nat Cancer</journal-id>
      <journal-id journal-id-type="iso-abbrev">Nat Cancer</journal-id>
      <journal-title-group>
        <journal-title>Nature cancer</journal-title>
      </journal-title-group>
      <issn pub-type="epub">2662-1347</issn>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">33521652</article-id>
      <article-id pub-id-type="pmc">7842382</article-id>
      <article-id pub-id-type="doi">10.1038/s43018-019-0020-z</article-id>
      <article-id pub-id-type="manuscript">NIHMS1586579</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Stewart</surname>
            <given-names>C. Allison</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
          <xref rid="FN3" ref-type="author-notes">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gay</surname>
            <given-names>Carl M.</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
          <xref rid="FN3" ref-type="author-notes">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Xi</surname>
            <given-names>Yuanxin</given-names>
          </name>
          <xref ref-type="aff" rid="A2">2</xref>
          <xref rid="FN3" ref-type="author-notes">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sivajothi</surname>
            <given-names>Santhosh</given-names>
          </name>
          <xref ref-type="aff" rid="A3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sivakamasundari</surname>
            <given-names>V.</given-names>
          </name>
          <xref ref-type="aff" rid="A3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Fujimoto</surname>
            <given-names>Junya</given-names>
          </name>
          <xref ref-type="aff" rid="A4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bolisetty</surname>
            <given-names>Mohan</given-names>
          </name>
          <xref ref-type="aff" rid="A3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hartsfield</surname>
            <given-names>Patrice M.</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Balasubramaniyan</surname>
            <given-names>Veerakumar</given-names>
          </name>
          <xref ref-type="aff" rid="A5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Chalishazar</surname>
            <given-names>Milind D.</given-names>
          </name>
          <xref ref-type="aff" rid="A6">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Moran</surname>
            <given-names>Cesar</given-names>
          </name>
          <xref ref-type="aff" rid="A7">7</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kalhor</surname>
            <given-names>Neda</given-names>
          </name>
          <xref ref-type="aff" rid="A7">7</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Stewart</surname>
            <given-names>John</given-names>
          </name>
          <xref ref-type="aff" rid="A7">7</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tran</surname>
            <given-names>Hai</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Swisher</surname>
            <given-names>Stephen G.</given-names>
          </name>
          <xref ref-type="aff" rid="A8">8</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Roth</surname>
            <given-names>Jack A.</given-names>
          </name>
          <xref ref-type="aff" rid="A8">8</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Zhang</surname>
            <given-names>Jianjun</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>de Groot</surname>
            <given-names>John</given-names>
          </name>
          <xref ref-type="aff" rid="A5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Glisson</surname>
            <given-names>Bonnie</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Oliver</surname>
            <given-names>Trudy G.</given-names>
          </name>
          <xref ref-type="aff" rid="A6">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Heymach</surname>
            <given-names>John V.</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wistuba</surname>
            <given-names>Ignacio</given-names>
          </name>
          <xref ref-type="aff" rid="A4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Robson</surname>
            <given-names>Paul</given-names>
          </name>
          <xref ref-type="aff" rid="A3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>Jing</given-names>
          </name>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Byers</surname>
            <given-names>Lauren Averett</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
      </contrib-group>
      <aff id="A1"><label>1</label>Department of Thoracic/Head &amp; Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA</aff>
      <aff id="A2"><label>2</label>Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA</aff>
      <aff id="A3"><label>3</label>The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA</aff>
      <aff id="A4"><label>4</label>Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA</aff>
      <aff id="A5"><label>5</label>Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA</aff>
      <aff id="A6"><label>6</label>Department of Oncological Sciences, University of Utah, Huntsman Cancer Institute, Salt Lake City, UT, USA</aff>
      <aff id="A7"><label>7</label>Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA</aff>
      <aff id="A8"><label>8</label>Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA</aff>
      <author-notes>
        <fn fn-type="con" id="FN1">
          <p id="P1">AUTHOR CONTRIBUTIONS</p>
          <p id="P2">C.A.S., C.M.G., Y.X., and L.A.B. conceived the project, analyzed and interpreted the data, and wrote the manuscript; S.S., S.V., and V.B., contributed to acquisition of data; J.F., C.M., N.K., J.S., and I.W. performed pathology review and analysis; M.B., and J.W. contributed to the analysis and interpretation of data; P.M.H. collected patient liquid biopsies; H.T. coordinated patient protocol; P.R., J.Z., B.G., J.G., S.G.S., J.A.R., M.D.C., T.G.O. and J.V.H. contributed to the acquisition of data, administrative, and/or material support. All authors contributed to the writing, review, and/or revision of the manuscript.</p>
        </fn>
        <fn fn-type="equal" id="FN3">
          <label>*</label>
          <p id="P3">These authors contributed equally</p>
        </fn>
        <fn fn-type="COI-statement" id="FN4">
          <p id="P55">COMPETING INTERESTS STATEMENT</p>
          <p id="P56">L.A.B. serves on advisory committees for AstraZeneca, AbbVie, GenMab, BergenBio, Pharma Mar SA, Sierra Oncology, Merck, Bristol Myers Squibb, Genentech, and Pfizer and has research support from AbbVie, AstraZeneca, GenMab, Sierra Oncology, Tolero Pharmaceuticals. J.V.H. serves on advisory committees for AstraZeneca, Boehringer Ingelheim, Exelixis, Genentech, GSK, Guardant Health, Hengrui, Lilly, Novartis, Spectrum, EMD Serono, and Synta, has research support from AstraZeneca, Bayer, GlaxoSmithKline, and Spectrum and royalties and licensing fees from Spectrum. Otherwise, there are no pertinent financial or non-financial conflicts of interest to report.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="nihms-submitted">
        <day>25</day>
        <month>4</month>
        <year>2020</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>17</day>
        <month>2</month>
        <year>2020</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>4</month>
        <year>2020</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>01</day>
        <month>4</month>
        <year>2021</year>
      </pub-date>
      <volume>1</volume>
      <fpage>423</fpage>
      <lpage>436</lpage>
      <!--elocation-id from pubmed: 10.1038/s43018-019-0020-z-->
      <self-uri xlink:href="https://www.nature.com/articles/s43018-019-0020-z"/>
      <abstract id="ABS1">
        <p id="P4">The natural history of small cell lung cancer (SCLC) includes rapid evolution from chemosensitivity to chemoresistance, although mechanisms underlying this evolution remain obscure due to scarcity of post-relapse tissue samples. We generated circulating tumor cell (CTC)-derived xenografts (CDXs) from SCLC patients to study intratumoral heterogeneity (ITH) via single-cell RNAseq of chemo-sensitive and -resistant CDXs and patient CTCs. We found globally increased ITH including heterogeneous expression of therapeutic targets and potential resistance pathways, such as EMT, between cellular subpopulations following treatment-resistance. Similarly, serial profiling of patient CTCs directly from blood confirmed increased ITH post-relapse. These data suggest that treatment-resistance in SCLC is characterized by coexisting subpopulations of cells with heterogeneous gene expression leading to multiple, concurrent resistance mechanisms. These findings emphasize the need for clinical efforts to focus on rational combination therapies for treatment-na√Øve SCLC tumors to maximize initial responses and counteract the emergence of ITH and diverse resistance mechanisms.</p>
      </abstract>
      <kwd-group>
        <kwd>SCLC</kwd>
        <kwd>CDX</kwd>
        <kwd>CTC</kwd>
        <kwd>single-cell RNAseq</kwd>
        <kwd>intratumoral heterogeneity</kwd>
      </kwd-group>
    </article-meta>
  </front>
</article>
</pmc-articleset>
